Delivery Order SPE2DB22D2007-SPE2DB25FJ5MA
- Not listed
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for Ondansetron ODT 4 mg tablets (30-count) valued at $4,536.73 under a firm fixed-price contract type. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a non-set-aside award, indicating it was competitively awarded. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 1, 2025, by the Defense Logistics Agency's Medical Supply Chain to provide Ondansetron ODT 4 mg tablets (30-count) with a firm fixed price ceiling value of $5,173.92. The order is scheduled for completion by August 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs, consistent with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at approximately $29,900 on September 23, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, reflecting the contractor's ability to compete in open procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count) with a contract ceiling value of $4,122.98. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by September 12, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, valued at $13,303.54. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is set to complete by September 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 30, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply Ondansetron ODT 8 mg tablets in a 30-count quantity. This is a non-set-aside, competitively awarded firm fixed price delivery order with a ceiling value of $1,438.73 and an ultimate completion date of July 31, 2025. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 12, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. This is a firm fixed-price, non-set-aside contract with a ceiling value of $5,923.61 and an ultimate completion date of September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency's Medical Supply Chain for Ondansetron ODT 4 mg tablets (30-count units) valued at $31,190.34. The contract was awarded on September 18, 2025, with an ultimate completion date of September 19, 2025, and carries firm fixed pricing with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this delivery order,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a ceiling value of $18,294.19. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by September 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count) with a ceiling value of $1,254.19 on August 4, 2025. This firm fixed-price delivery order, which is scheduled for completion by August 5, 2025, represents a non-competitive set-aside award under AmerisourceBergen's existing contract vehicle with DLA. The pharmaceutical distributor will perform the work at its corporate office location in Conshohocken, Pennsylvania....
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5MADelivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) on September 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract value of $14,262.22. This is a firm fixed-price, non-set-aside delivery order with a completion deadline of September 30, 2025. The awardee will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a broad range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. The DLA selected AmerisourceBergen competitively through open competition, reflecting the company's established capability to meet federal pharmaceutical procurement requirements across multiple therapeutic domains and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.3k | 9/29/25 |